C3 Antikörper (C-Term)

Produktnummer ABIN1106781

Dieses Anti-C3-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von C3 in WB und EIA. Geeignet für Human.

Kurzübersicht für C3 Antikörper (C-Term) (ABIN1106781)

Target: C3 (Complement Component 3 (C3))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser C3 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Klon: 2898

Produktdetails anti-C3 Antikörper

Bindungsspezifität: C-Term

Sequenz: CARASHLGLA

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Protein G

Immunogen: Peptide (last nine amino acids of C3a-desArg)

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2 - 8 °C.

Details zu C3

Target: C3 (Complement Component 3 (C3))

Andere Bezeichnung: Complement C3

Hintergrund: C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/mL. The complement system is an important part of the humoral response in innate immunity, consisting of three different pathways. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 releasing C3a anaphylatoxin and C3b. C3a is a protein of 74 amino acids. C3a itself is very short-lived and in serum is cleaved rapidly into the more stable C3a-desArg (also called acylation stimulating protein, ASP). Therefore, measurement of C3a-desArg allows reliable conclusions about the level of complement activation in the test samples. C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases.Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, CPAMD1, Complement component 3

Gen-ID: 9606

UniProt: P01024

Pathways: Komplementsystem, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Regulation of G-Protein Coupled Receptor Protein Signaling